GE Healthcare: GE Healthcare Launches AI-Driven, Patient-Friendly Invenia Abus Premium to Accelerate Scanning and Drive Early Cancer Detection in Dense Breast Breast Cancer Detection in Dense Breast Cancer

GE HealthCare announced the launch of Invenia Automated Breast Ultrasound (ABUS) Premium, the latest 3D ultrasound offering advanced artificial intelligence (AI) and innovative features to drive faster, reproducible supplemental screening and streamline exam readings on patients with dense breasts. Approximately 71% of cancers occur in dense breasts. According to studies across the U.S. and Europe, 40% of women and 70% of Asian women have dense breast tissue, making them four to six times more likely to receive a breast cancer diagnosis. Early detection of breast cancer is critical, yet about one-third5 of cancers in dense breasts may go undetected by a mammogram, as the cancer can be masked within the dense tissue. There is rapidly growing evidence supporting ABUS as a valuable tool for detecting cancer in dense breasts because it provides better and more detailed images and has been shown to improve the sensitivity of detecting invasive cancer in dense breasts when added to mammography. Invenia ABUS Premium is designed to manage high patient volumes along the breast care pathway, while delivering extraordinary image quality and boosting clinical confidence. The new Verisound AItools can help clinicians work smarter and more efficiently, featuring Scan Quality Assessment for immediate qualitative evaluation during the exam for proper breast coverage and positioning, and Auto Nipple Detection for consistent nipple marker positions. The new Fast Scan tool increases scan speed by up to 40%, while cSound Imageformer capabilities automatically create focus at every pixel, ensuring consistent, high-resolution image quality and reproducible scanning and reading with extraordinary image quality. For fast, streamlined reading, physicians can use Invenia ABUS Viewer with AI Assistant to quickly review and interpret patient exams either from their practice or remotely. The integration of AI tools for enhanced review of ABUS 3D datasets harness intelligent algorithms to assist in detecting and characterizing breast lesions. These tools can help improve clinical confidence and reading efficiency, addressing staff shortages. The ABUS Premium's non-invasive design significantly enhances the patient experience, with a patient experience study showing that 100% of women would recommend an ABUS exam to their best friend.10 This advanced ABUS technology also has the potential to reduce unnecessary biopsies by providing specific image features to distinguish and detect malignant tumors, enabling clinicians to escalate care sooner. Additionally, it reduces patient exposure to radiation or contrast injection as it doesn't use any iodinated contrast agent or ionizing radiation. The new Reverse Curve transducer follows the contour of a woman's breast anatomy, while selectable compression levels provide personalized comfort during the exam. There has been great improvement in image quality with less shadowing, and the structures behind the area of the breast are seen more clearly, providing radiologists with greater diagnostic confidence." Invenia ABUS Premium will be launching in key countries throughout 2025 and received Premarket Approval (PMA) from the U.S. Food and Drug Administration. GE HealthCare announced the launch of Invenia Automated Breast Ultrasound (ABUS) Premium, the latest 3D ultrasound offering advanced artificial intelligence (AI) and innovative features to drive faster, reproducible supplemental screening and streamline exam readings on patients with dense breasts. Approximately 71% of cancers occur in dense breasts. According to studies across the U.S. and Europe, 40% of women and 70% of Asian women have dense breast tissue, making them four to six times more likely to receive a breast cancer diagnosis. Early detection of breast cancer is critical, yet about one-third5 of cancers in dense breasts may go undetected by a mammogram, as the cancer can be masked within the dense tissue. There is rapidly growing evidence supporting ABUS as a valuable tool for detecting cancer in dense breasts because it provides better and more detailed images and has been shown to improve the sensitivity of detecting invasive cancer in dense breasts when added to mammography. Invenia ABUS Premium is designed to manage high patient volumes along the breast care pathway, while delivering extraordinary image quality and boosting clinical confidence. The new Verisound AItools can help clinicians work smarter and more efficiently, featuring Scan Quality Assessment for immediate qualitative evaluation during the exam for proper breast coverage and positioning, and Auto Nipple Detection for consistent nipple marker positions. The new Fast Scan tool increases scan speed by up to 40%, while cSound Imageformer capabilities automatically create focus at every pixel, ensuring consistent, high-resolution image quality and reproducible scanning and reading with extraordinary image quality. For fast, streamlined reading, physicians can use Invenia ABUS Viewer with AI Assistant to quickly review and interpret patient exams either from their practice or remotely. The integration of AI tools for enhanced review of ABUS 3D datasets harness intelligent algorithms to assist in detecting and characterizing breast lesions. These tools can help improve clinical confidence and reading efficiency, addressing staff shortages. The ABUS Premium's non-invasive design significantly enhances the patient experience, with a patient experience study showing that 100% of women would recommend an ABUS exam to their best friend.10 This advanced ABUS technology also has the potential to reduce unnecessary biopsies by providing specific image features to distinguish and detect malignant tumors, enabling clinicians to escalate care sooner. Additionally, it reduces patient exposure to radiation or contrast injection as it doesn't use any iodinated contrast agent or ionizing radiation. The new Reverse Curve transducer follows the contour of a woman's breast anatomy, while selectable compression levels provide personalized comfort during the exam. There has been great improvement in image quality with less shadowing, and the structures behind the area of the breast are seen more clearly, providing radiologists with greater diagnostic confidence." Invenia ABUS Premium will be launching in key countries throughout 2025 and received Premarket Approval (PMA) from the U.S. Food and Drug Administration.